Q4 2025 DaVita Inc Earnings Call Transcript
Key Points
- DaVita Inc (DVA) achieved its first profitable year in its Integrated Kidney Care (IKC) program, slightly ahead of schedule.
- The company reported strong clinical outcomes in its IKC programs, with patients experiencing fewer bloodstream infections and higher vaccination rates.
- DaVita Inc (DVA) delivered adjusted operating income and adjusted earnings per share in the top half of its guidance range for the full year 2025.
- The company announced a strategic clinical partnership with Elara Caring to enhance patient care and reduce hospitalizations.
- DaVita Inc (DVA) expects to deliver an incremental $20 million of IKC operating income growth in 2026, indicating continued confidence in its business model.
- DaVita Inc (DVA) faced higher-than-expected health benefit costs, which partially offset revenue growth.
- The company is managing financial headwinds, including continued pressure on treatment growth driven by elevated mortality rates.
- There is a revenue per treatment impact from the expiration of enhanced premium tax credits, posing a challenge for 2026.
- DaVita Inc (DVA) experienced a decline in US dialysis treatments by 1.1% for the full year 2025 compared to 2024.
- The company anticipates a typical $5 or more revenue per treatment headwind in the first quarter of 2026 due to patient responsibility amounts.
Good evening. My name is Michelle, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the DaVita fourth-quarter 2025 earnings call. (Operator Instructions)
Thank you, Mr. Eliason, you may begin your conference.
Thank you, and welcome to our fourth-quarter conference call. I'm Nic Eliason, Group Vice President of Investor Relations, and joining me today are Javier Rodriguez, our CEO; and Joel Ackerman, our CFO.
Please note that during this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements.
For further details concerning these risks and uncertainties, please refer to our fourth-quarter earnings press release and our SEC filings, including our most recent annual report on Form 10-K, all
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
